Form 4: Sangamo Therapeutics Executive Stock Tax Withholding

Scott B. Willoughby, SVP and Chief Legal Officer of Sangamo Therapeutics, reported a mandatory tax withholding transaction of 4,036 shares.

Summary

• Scott B. Willoughby, SVP and Chief Legal Officer of Sangamo Therapeutics, Inc., disposed of 4,036 shares of common stock.
• The transaction occurred on May 25, 2026, at a price of $0.1743 per share.
• The disposal was a non-discretionary action to satisfy mandatory tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 647,370 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing that carries no implications for the company's operational health or market outlook.

Positives

• The transaction was a routine, non-discretionary tax withholding event rather than an open-market sale, indicating no change in the executive's long-term confidence in the company.

Negatives

• The transaction reflects a low share price of $0.1743, highlighting the company's current depressed valuation.

Risks

• Continued reliance on equity-based compensation in a low-share-price environment may lead to further dilution or tax-related share dispositions.

Future Outlook

The filing does not provide forward-looking business guidance, focusing solely on the reporting of executive equity transactions.

Management Comments

• The transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

StockSavvy.ai notes that mandatory tax withholding filings are standard administrative procedures for biotech executives and do not typically signal shifts in corporate strategy or insider sentiment regarding company performance.

Comparison to Industry Standards

• The use of net-settlement for RSU tax obligations is a standard practice across the biotechnology and pharmaceutical sectors to manage executive tax liabilities without requiring open-market sales.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax settlement.

Next Steps

• The reporting person will continue to vest in remaining RSU grants in 7 successive equal quarterly installments.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Tax Withholding, Biotech